JP2022523333A - 抗ｇａｌ３抗体およびその使用 - Google Patents

抗ｇａｌ３抗体およびその使用 Download PDF

Info

Publication number
JP2022523333A
JP2022523333A JP2021544701A JP2021544701A JP2022523333A JP 2022523333 A JP2022523333 A JP 2022523333A JP 2021544701 A JP2021544701 A JP 2021544701A JP 2021544701 A JP2021544701 A JP 2021544701A JP 2022523333 A JP2022523333 A JP 2022523333A
Authority
JP
Japan
Prior art keywords
antibody
gal3
cells
less
tim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021544701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523333A5 (enExample
Inventor
サン，ドンフ
ワン，ヤン
ウ，イーナン
エー． ゴードン，キャサリン
ジェイシー モニエ，ジャスティン
エーエフ ウィリアムス，サムエル
ジェイ パテル，マンダキニ
ツァイ，ツンファン
Original Assignee
トゥルーバインディング，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トゥルーバインディング，インコーポレイテッド filed Critical トゥルーバインディング，インコーポレイテッド
Publication of JP2022523333A publication Critical patent/JP2022523333A/ja
Publication of JP2022523333A5 publication Critical patent/JP2022523333A5/ja
Priority to JP2025028358A priority Critical patent/JP2025074121A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2021544701A 2019-01-30 2020-01-29 抗ｇａｌ３抗体およびその使用 Ceased JP2022523333A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025028358A JP2025074121A (ja) 2019-01-30 2025-02-25 抗ｇａｌ３抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962798949P 2019-01-30 2019-01-30
US201962798945P 2019-01-30 2019-01-30
US62/798,945 2019-01-30
US62/798,949 2019-01-30
PCT/US2020/015692 WO2020160156A2 (en) 2019-01-30 2020-01-29 Anti-gal3 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025028358A Division JP2025074121A (ja) 2019-01-30 2025-02-25 抗ｇａｌ３抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2022523333A true JP2022523333A (ja) 2022-04-22
JP2022523333A5 JP2022523333A5 (enExample) 2023-02-07

Family

ID=71842280

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544701A Ceased JP2022523333A (ja) 2019-01-30 2020-01-29 抗ｇａｌ３抗体およびその使用
JP2025028358A Withdrawn JP2025074121A (ja) 2019-01-30 2025-02-25 抗ｇａｌ３抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025028358A Withdrawn JP2025074121A (ja) 2019-01-30 2025-02-25 抗ｇａｌ３抗体およびその使用

Country Status (8)

Country Link
US (2) US11427638B2 (enExample)
EP (1) EP3918323A4 (enExample)
JP (2) JP2022523333A (enExample)
KR (1) KR20210124308A (enExample)
CN (4) CN113711036B (enExample)
AU (1) AU2020214796A1 (enExample)
CA (1) CA3127113A1 (enExample)
WO (1) WO2020160156A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548627A (ja) * 2019-09-16 2022-11-21 ノバルティス アーゲー 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
JP7802400B1 (ja) * 2024-10-18 2026-01-20 Ｓｍｃグローバルアセット株式会社 物質の投与による効果の評価を行う方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
JP7181438B2 (ja) * 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
JP7835441B2 (ja) * 2019-12-06 2026-03-25 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
BR112022013892A2 (pt) * 2020-01-13 2022-10-04 Truebinding Inc Anticorpos anti-gal3 e métodos de uso
EP4157338A4 (en) * 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2022125482A1 (en) * 2020-12-08 2022-06-16 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
US20240124606A1 (en) * 2021-02-22 2024-04-18 Northwestern University Anti-cd73 monoclonal antibodies
JP2024515968A (ja) * 2021-04-26 2024-04-11 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体製剤およびその使用法
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
US20220411514A1 (en) * 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance
EP4352107A4 (en) * 2021-06-11 2025-07-23 Memorial Sloan Kettering Cancer Center ANTI-UPAR ANTIBODIES AND THEIR USES
JP2024526764A (ja) * 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
CN118524852A (zh) 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
US20250277016A1 (en) * 2022-04-22 2025-09-04 The United States Government As Represented By The Department Of Veterans Affairs Antibodies and methods of use
CN116558774B (zh) * 2023-04-19 2024-08-30 哈尔滨工程大学 一种自由航行的通气超空泡航行体实验模型及使用方法
CN118286392A (zh) * 2024-03-28 2024-07-05 广州医科大学附属妇女儿童医疗中心 重组Galectin-3在治疗慢性炎性脱髓鞘性多发性神经根神经病中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143954A1 (en) * 2008-10-29 2010-06-10 Bg Medicine, Inc. Galectin-3 Immunoassay
US20150218274A1 (en) * 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof
JP2017512205A (ja) * 2014-03-10 2017-05-18 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎臓障害を治療するための組成物及び方法
WO2019023247A1 (en) * 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
JP2023504199A (ja) * 2019-12-06 2023-02-01 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
JP2023510866A (ja) * 2020-01-13 2023-03-15 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体および使用方法

Family Cites Families (769)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JPH01207920A (ja) 1988-02-16 1989-08-21 Oki Electric Ind Co Ltd ＩｎＰ半導体薄膜の製造方法
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
AU679167B2 (en) 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
AU683703B2 (en) 1993-10-20 1997-11-20 Duke University Method of binding material to the beta-amyloid peptide
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
WO1996006862A1 (en) 1994-08-26 1996-03-07 Human Genome Sciences, Inc. Gabaa receptor epsilon subunit
DE69535901D1 (de) 1994-10-28 2009-01-29 Max Planck Gesellschaft Proteinkinase npk-110
US6835555B1 (en) 1994-11-01 2004-12-28 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5650313A (en) 1995-06-05 1997-07-22 Human Genome Sciences, Inc. Ubiquitin conjugating enzymes 8 and 9
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
JP4073955B2 (ja) 1995-07-07 2008-04-09 ダーウィン モレキュラー コーポレイション アルツハイマー病に関連する第１染色体の遺伝子および遺伝子産物
US6156311A (en) 1995-07-27 2000-12-05 The American National Red Cross Modulators of expression and function of LRP in alzheimer's disease
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
AUPN896596A0 (en) 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
WO1997037228A1 (en) 1996-03-29 1997-10-09 The Trustees Of Boston University Methods for diagnosing and treating alzheimer's disease
US6455277B1 (en) 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US5663059A (en) 1996-05-10 1997-09-02 Incyte Pharmaceuticals, Inc. Human phospholipase inhibitor
US6010878A (en) 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
PT966533E (pt) 1997-02-07 2010-01-26 Univ Ramot Factor neurotrófico iii dependente da actividade (adnf iii)
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US6087153A (en) 1997-07-24 2000-07-11 The Trustees Of Columbia University In The City Of New York Sel-10 and uses thereof
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US7384910B2 (en) 1997-10-08 2008-06-10 Castillo Gerardo M Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7189703B2 (en) 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
GB9816575D0 (en) 1998-07-31 1998-09-30 Zeneca Ltd Novel compounds
AU5065399A (en) 1998-08-06 2000-02-28 Teijin Limited Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
US20050032675A1 (en) 1998-08-06 2005-02-10 Teijin Limited Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DE69925133T2 (de) 1998-08-27 2006-01-19 Spirogen Ltd., Ryde Pyrrolobenzodiazepine
WO2000017345A1 (en) 1998-09-17 2000-03-30 Otsuka Pharmaceutical Co., Ltd. Ly6h gene
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000032805A1 (en) 1998-12-02 2000-06-08 The Trustees Of The University Of Pennsylvania Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
DE19909357A1 (de) 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
DE19910108C2 (de) 1999-03-08 2001-02-22 Falk Fahrenholz Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie
AU4055000A (en) 1999-04-13 2000-11-14 Daniel K. Hsu Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1201754A4 (en) 1999-07-08 2005-02-09 Fujisawa Pharmaceutical Co FACTOR ASSOCIATED WITH APOPTOSIS
EP1074634B1 (en) 1999-07-09 2002-10-02 Institut Pasteur De Lille Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease
AU783964B2 (en) 1999-08-06 2006-01-05 S.I.S.S.A. Scuola Internazionale Superiore Di Studi Avanzati Non-human transgenic animals for the study of neurodegenerative syndromes
AU784568B2 (en) 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6255054B1 (en) 1999-09-09 2001-07-03 Jacques Hugon Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
JP4969006B2 (ja) 1999-09-17 2012-07-04 学校法人慶應義塾 神経細胞死を抑制するポリペプチド、Ｈｕｍａｎｉｎ
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ATE490979T1 (de) 2000-02-14 2010-12-15 Takeshi Iwatsubo Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
US20060148712A1 (en) 2000-03-13 2006-07-06 Fu-Tong Liu Monocyte chemoattractant activity of galectin-3
US7186681B2 (en) 2000-03-13 2007-03-06 La Jolla Institute For Allergy And Immunology Methods of modulating cell migration using galectin-3
CN1450908A (zh) 2000-06-28 2003-10-22 普拉纳生物技术有限公司 神经毒性寡聚体
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
WO2002026246A2 (en) 2000-09-29 2002-04-04 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Pharmaceutical compositions comprising polynucleotides encoding a raf protein
US7471798B2 (en) 2000-09-29 2008-12-30 Knowles Electronics, Llc Microphone array having a second order directional pattern
KR100395254B1 (ko) 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
CA2671776C (en) * 2001-01-31 2012-12-18 H. Lundbeck A/S Gal3 receptor antagonists for the treatment of depression
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AU2002254029A1 (en) 2001-02-27 2002-09-12 Daniel L. Alkon Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
ATE401576T1 (de) 2001-04-14 2008-08-15 Evotec Neurosciences Gmbh Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP2165714B1 (en) 2001-04-30 2013-10-23 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DE10130247A1 (de) 2001-06-22 2003-01-16 Elegene Ag I Ins Identifizierung von ses-3 sowie dessen Verwendungen
DE10130166A1 (de) 2001-06-22 2003-01-16 Elegene Ag I Ins Identifizierung von ses-1 sowie dessen Verwendungen
US6831699B2 (en) 2001-07-11 2004-12-14 Chang Industry, Inc. Deployable monitoring device having self-righting housing and associated method
DE60226036T9 (de) 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
EP1423704B1 (en) 2001-09-07 2010-04-14 Takeda Pharmaceutical Company Limited Diagnostic and therapeutic use of f-box proteins for alzheimer's disease and related neurodegenerative disorders
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
DE60303360T2 (de) 2002-02-14 2006-09-21 Evotec Neurosciences Gmbh Diagnostische und therapeutische verwendung des caps
WO2003074558A2 (en) 2002-03-04 2003-09-12 Nymox Corporation Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
WO2003076455A2 (en) 2002-03-05 2003-09-18 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ATE365175T1 (de) 2002-03-21 2007-07-15 Evotec Neurosciences Gmbh Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten
ATE514707T1 (de) 2002-04-19 2011-07-15 Univ Toronto Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer
EP1497661B1 (en) 2002-04-24 2009-11-25 EVOTEC Neurosciences GmbH Diagnostic use of ensadin-0477 gene and protein for neurodegenerative diseases
US20050032673A1 (en) 2002-06-10 2005-02-10 John Constance M. Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease
US7409040B2 (en) 2002-06-21 2008-08-05 Reuven Avrohom Cyrulnik System and method for noninvasive diagnostic imaging, detection, and identification of substances by microwave/RF modulation of x-rays and applications in treatment of diseases characterized by the presence of pathological macromolecules or by the need for regeneration of normal tissue
AU2003260301A1 (en) 2002-06-27 2004-01-19 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
US7141137B2 (en) 2002-07-10 2006-11-28 University Of Maine System Board Of Trustees Method of making laminated wood beams with varying lamination thickness throughout the thickness of the beam
US20060167227A1 (en) 2002-07-12 2006-07-27 Axon Neuroscience Forschungs-Und Entwicklungs Gmbh Truncated tau proteins
EP2338510A1 (en) 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
NZ567324A (en) 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
EP1590673B1 (en) 2003-02-04 2009-04-15 EVOTEC Neurosciences GmbH Diagnostic use of scn2b for alzheimer's disease
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20040223971A1 (en) 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
DE602004014485D1 (de) 2003-04-07 2008-07-31 Prospect Therapeutics Inc Zusammensetzung und anwendungen von galectin-antagonisten
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246178B1 (es) 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2004111654A2 (en) 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
US7384523B2 (en) 2003-07-10 2008-06-10 Radiometer Medical Aps Chloride ion selective membrane and sensor
ES2284018T3 (es) 2003-07-28 2007-11-01 Sig Technology Ltd. Tapon vertedor con dispositivo cortador punzante para embases combinados o recipientes cerrados con meterial en laminas.
WO2005016876A2 (en) 2003-08-08 2005-02-24 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
AR045219A1 (es) 2003-08-08 2005-10-19 Pharmacopeia Inc Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
US7625711B2 (en) 2003-09-05 2009-12-01 Hisamitsu Pharmaceutical Co., Inc. Screening method for the identification of a drug for the development of an agent for prevention and/or treatment of Alzheimer's disease
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
EP1670943B1 (en) 2003-09-30 2013-11-13 Evotec International GmbH Diagnostic and therapeutic use of a sulfotransferase for alzheimer's disease
US7700823B2 (en) 2003-10-02 2010-04-20 Aventis Pharma S.A. Transgenic animals exhibiting major disorders related to Alzheimer's disease
CA2541006C (en) 2003-10-03 2015-02-17 Brigham And Women's Hospital Tim-3 polypeptides
GB0416511D0 (en) 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
EP1678505B1 (en) 2003-10-29 2014-08-06 Evotec International GmbH Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20050158321A1 (en) 2003-12-17 2005-07-21 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
WO2005063761A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
US8060179B1 (en) 2006-11-16 2011-11-15 Scientific Nanomedicine, Inc. Biomagnetic detection and treatment of Alzheimer's Disease
EP1721008B1 (en) 2004-03-03 2010-02-24 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
JP2007528400A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
WO2005085260A1 (en) 2004-03-09 2005-09-15 Spirogen Limited Pyrrolobenzodiazepines
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
CA2564432A1 (en) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
US7629443B2 (en) 2004-06-02 2009-12-08 New York Blood Center, Inc. Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
EP1794313B1 (en) 2004-06-21 2013-05-15 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
WO2006014638A2 (en) 2004-07-19 2006-02-09 The General Hospital Corporation ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
US20060024667A1 (en) 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
CA2575340A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
CA2576405A1 (en) 2004-08-11 2006-02-16 Mitsubishi Chemical Corporation Antibody and utilization of the same
JP2008508893A (ja) 2004-08-11 2008-03-27 エボテツク・ニユーロサイエンシーズ・ゲー・エム・ベー・ハー 形質膜ａｔｐアーゼの診断及び治療への使用
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
ATE459650T1 (de) 2004-10-08 2010-03-15 Univ Liege KOMPLEMENTÄRE PEPTIDE FÜR ß-AMYLOID 29-42-PEPTID
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US7811563B2 (en) 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
WO2006067198A2 (en) 2004-12-22 2006-06-29 Direvo Biotech Ag Targeted use of engineered enzymes
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
WO2006112553A2 (en) 2005-04-20 2006-10-26 Dnavec Corporation Highly safe intranasally administrable gene vaccines for treating alzheimer's disease
US7612062B2 (en) 2005-04-21 2009-11-03 Spirogen Limited Pyrrolobenzodiazepines
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP1879613B1 (en) 2005-05-05 2011-11-30 Merck Sharp & Dohme Corp. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US8114620B2 (en) 2005-05-30 2012-02-14 Takeda Pharmaceutical Company Limited Diagnostic and therapeutic target PRKX proteins for neurodegenerative diseases
EP1891234B1 (en) 2005-06-01 2014-12-10 Evotec International GmbH Use of slc39a12 proteins as target in diagnosis and drug screening in alzheimer's disease
WO2006138265A2 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
ATE489370T1 (de) 2005-06-14 2010-12-15 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
WO2006134128A2 (en) 2005-06-16 2006-12-21 Evotec Neurosciences Gmbh Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
ATE439443T1 (de) 2005-06-17 2009-08-15 Ca Nat Research Council NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
DE102005029729A1 (de) 2005-06-24 2006-12-28 Röchling Automotive AG & Co. KG Verkleidungs- oder Gehäuseteil eines Fahrzeugs und Verfahren zu seiner Herstellung
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US20070021282A1 (en) 2005-07-19 2007-01-25 Karp Shaun A Abdominal exercising and strength testing systems
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
US9133267B2 (en) 2005-11-22 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
JP2009518010A (ja) 2005-11-30 2009-05-07 アボット・ラボラトリーズ ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
RS52060B (sr) 2006-01-25 2012-04-30 Sanofi Citotoksični agensi koji sadrže nove derivate tomaimicina
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
JP5097695B2 (ja) 2006-02-22 2012-12-12 株式会社林原 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
EP2005187A4 (en) 2006-03-23 2010-04-21 Life Technologies Corp METHOD AND REAGENTS FOR IN VIVO IMAGING CANCER CELL LINES
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2011513B1 (en) 2006-04-25 2016-10-19 The University of Tokyo Therapeutic agents for alzheimer's disease and cancer
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
US8141022B2 (en) 2006-07-06 2012-03-20 Nec Corporation Method and apparatus for hierarchical design of semiconductor integrated circuit
CN101501696A (zh) * 2006-08-14 2009-08-05 麻省理工学院 聚糖数据挖掘系统
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008029886A1 (en) 2006-09-06 2008-03-13 National University Corporation Tottori University Kit for diagnosis of alzheimer's disease, diagnostic marker, and method for detection of indicator for disease condition
WO2008036717A2 (en) 2006-09-19 2008-03-27 Emory University Use of soluble galectin-3 (gal-3) for cancer treatment
WO2008085564A2 (en) 2006-09-20 2008-07-17 The Board Of Regents Of The University Of Texas System Compositions and methods involving truncated recombinant seven g-protein coupled receptors
EP2094832B1 (en) 2006-11-15 2015-04-22 The J. David Gladstone Institutes Methods and compositions for reducing amyloid beta levels
EP2081961A2 (en) 2006-11-15 2009-07-29 The Brigham and Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US8420591B2 (en) 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
BRPI0806340B8 (pt) 2007-01-09 2021-05-25 Biogen Idec Inc anticorpo isolado que se liga especificamente a sp35, seu uso e composição farmacêutica
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
DK2121754T3 (en) 2007-01-18 2015-02-23 Lilly Co Eli Pegylated amyloid BETA FAB
WO2008112559A1 (en) 2007-03-09 2008-09-18 Regents Of The University Of California Suppression of galectin-3 for treating an inflammatory condition
ES2655868T3 (es) 2007-04-20 2018-02-22 The Chemo-Sero-Therapeutic Research Institute Método para aumentar la respuesta inmunitaria con un péptido
EP2152744A4 (en) 2007-04-26 2012-02-15 Univ Yale PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS
US20100136597A1 (en) 2007-04-26 2010-06-03 Nathalie Demotte Method for modularting activity of t lymphocytes
WO2008141321A1 (en) 2007-05-14 2008-11-20 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
WO2009008980A2 (en) 2007-07-05 2009-01-15 Schering Corporation Tetrahydropyranochromene gamma secretase inhibitors
EP2178882B1 (en) 2007-07-17 2013-04-17 Merck Sharp & Dohme Corp. Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
US8993833B2 (en) 2007-08-14 2015-03-31 Duke University Model of Alzheimer's Disease
WO2009027105A2 (en) 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
US8518975B2 (en) 2007-09-06 2013-08-27 Merck Sharp + Dohme Corp. Gamma secretase modulators
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2224000B1 (en) 2007-10-29 2020-05-13 TAO Health Life Pharma Co., Ltd. Antibody and use thereof
MY155144A (en) 2007-10-29 2015-09-15 Inst Nat Sante Rech Med NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
EP2207885B1 (en) 2007-11-01 2013-11-20 F. Hoffmann-La Roche AG Quadruple transgenic non-human animal
MX2010005028A (es) 2007-11-05 2010-05-27 Schering Corp Moduladores de gamma secretasa.
KR101397554B1 (ko) 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
US8349579B2 (en) 2007-12-13 2013-01-08 Wayne State University Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer
US8883419B2 (en) 2008-01-07 2014-11-11 Council Of Scientific & Industrial Research Methods and kits useful for the identification of astrocytoma, it's grades and glioblastoma prognosis
ITNA20080006A1 (it) 2008-01-28 2009-07-29 Consiglio Nazionale Ricerche Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp
CN102936287B (zh) 2008-02-08 2015-09-09 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
CA2716521A1 (en) 2008-02-29 2009-09-11 Baxter Healthcare S.A. Anti-amyloid .beta. activity of intravenous immunoglobulin (ivig) in vitro
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
AU2009236699B2 (en) 2008-04-14 2013-09-05 Alzinova Ab Stable amyloid beta monomers and oligomers
EP2116556B1 (en) 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
WO2009146301A1 (en) 2008-05-27 2009-12-03 Yale University TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE
US8969023B2 (en) 2008-06-10 2015-03-03 Eleanore Bennett Charitable Trust #2 Methods and compositions for treating alzheimer's disease
EP2303001A4 (en) 2008-06-20 2016-07-13 Janssen Biotech Inc METHOD FOR VERIFYING THE EFFECTIVENESS OF TREATMENT OF NEUROLOGICAL ILLNESSES
WO2009155609A1 (en) 2008-06-20 2009-12-23 Oklahoma Medical Research Foundation IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
CN102112488A (zh) 2008-07-01 2011-06-29 由卫生福利和体育大臣代表的荷兰王国 抗淀粉样折叠中间体的疫苗
AU2009268808A1 (en) 2008-07-08 2010-01-14 Merck Sharp & Dohme Corp. Vaccine for the treatment of Alzheimer's disease
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
MX2011000655A (es) * 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
GB0813432D0 (en) 2008-07-22 2008-08-27 Spirogen Ltd Pyrrolobenzodiazepines
CA2735578C (en) 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
US8283322B2 (en) 2008-08-15 2012-10-09 Orthopeutics, Lp Formulations for nonsurgical exogenous crosslink therapy
WO2010040029A1 (en) 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
JP2012508748A (ja) 2008-11-13 2012-04-12 シェーリング コーポレイション γ−セクレターゼ調節剤
MX2011005046A (es) 2008-11-13 2011-06-01 Schering Corp Moduladores de gamma secretasa.
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
US8912145B2 (en) 2008-11-28 2014-12-16 Hokko Chemical Industry Co., Ltd. Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease
EP2373338B1 (en) 2008-12-03 2017-02-15 The Johns Hopkins University Annexina2 as immunological target
WO2010070043A1 (en) 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarkers for the diagnosis of renal allograft and kidney status
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
US20100196882A1 (en) 2009-02-04 2010-08-05 Avraham Raz GALECTIN-3 nsSNP MARKER FOR CANCER
RU2683325C2 (ru) 2009-02-05 2019-03-28 Иммьюноджен, Инк. Новые производные бензодиазепина
FR2942476B1 (fr) 2009-02-20 2013-03-15 Commissariat Energie Atomique Composes de type pyridocarbazole et leurs applications
HUE055739T2 (hu) 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
US9173928B2 (en) 2009-03-26 2015-11-03 Yoh Matsumoto DNA vaccine for Alzheimer's disease
JP2010268789A (ja) 2009-04-24 2010-12-02 Kumamoto Univ 細胞医薬の製造方法
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
WO2010146058A1 (en) 2009-06-15 2010-12-23 Vib Vzw Bace1 inhibitory antibodies
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
EP2273273A1 (en) 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease
US9312330B2 (en) 2009-07-15 2016-04-12 Fuji Electric Co., Ltd. Super-junction semiconductor device
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
SG177679A1 (en) 2009-08-07 2012-02-28 Kyowa Hakko Kirin Co Ltd Humanized anti-amyloid-b oligomer antibody
CN102576028A (zh) 2009-08-25 2012-07-11 保函医药公司 半乳凝集素-3和心脏再同步疗法
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
WO2011031720A1 (en) 2009-09-11 2011-03-17 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
DE102009043750A1 (de) 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
EP2489675A4 (en) 2009-10-16 2013-06-05 Univ Kyoto ANTIBODIES WITH RECOGNITION OF THE INVERTED STRUCTURE IN AN AMYLOID ß
WO2011102901A1 (en) 2010-02-20 2011-08-25 Ebiotec (Euroespes Biotechnology) Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphingosine-1-phosphate
JP6190113B2 (ja) 2010-03-03 2017-08-30 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア オリゴマー特異アミロイドベータエピトープおよび抗体
JP2013529181A (ja) 2010-03-25 2013-07-18 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 神経障害を治療するための組成物および方法
CN102946799A (zh) 2010-04-13 2013-02-27 巴克斯特国际公司 脑室增大率在阿尔茨海默病的静脉内免疫球蛋白治疗中的应用
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
CA2795349C (en) 2010-04-15 2016-11-29 Seattle Genetics, Inc. Targeted pyrrolobenzodiazepine conjugates
WO2011148668A1 (ja) 2010-05-25 2011-12-01 株式会社 島津製作所 大腸がんマーカーガレクチン、採血試料中のガレクチン濃度の分析方法及び大腸がんマーカーガレクチン検出キット
AU2011263642B2 (en) 2010-06-11 2014-09-04 Isarna Therapeutics Gmbh Method for selective oligonucleotide modification
EP2593475B1 (en) 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US10420923B1 (en) 2010-08-10 2019-09-24 Amiram Katz Method and device for intrathecal administering of immunoglobulin
PL3042917T3 (pl) 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
WO2012036786A1 (en) 2010-09-17 2012-03-22 University Of L'aquila Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease
AU2011323316B2 (en) 2010-11-03 2016-02-25 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
WO2012066495A2 (en) 2010-11-17 2012-05-24 Ben Gurion University Of The Negev Research And Development Authority T-cell therapy to neurodegenerative diseases
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
EP2660600B1 (en) 2010-12-28 2018-08-08 Sumitomo Dainippon Pharma Co., Ltd. Diagnostic drug and diagnostic method for alzheimer's disease
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
EP2508212A1 (en) 2011-04-05 2012-10-10 Universitätsklinikum Freiburg Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
KR101589135B1 (ko) 2011-04-20 2016-01-29 주식회사 셀앤바이오 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
US20140086836A1 (en) 2011-05-03 2014-03-27 Mental Health Research Institute Method for detection of a neurological disease
GB201108490D0 (en) 2011-05-18 2011-07-06 Ucl Business Plc Methods and uses
EP2710024A4 (en) 2011-05-19 2015-04-29 Harvard College OSW-1 ANALOGA AND CONJUGATES AND ITS USE
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
JP6209159B2 (ja) 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
WO2013008402A1 (ja) 2011-07-08 2013-01-17 シャープ株式会社 薄膜トランジスタ基板及びそれを備えた表示装置
GB201113482D0 (en) 2011-08-04 2011-09-21 Univ Liverpool Assay
NO2748201T3 (enExample) 2011-08-23 2018-05-12
WO2013042053A2 (en) 2011-09-19 2013-03-28 University Of The Witwatersrand, Johannesburg Compounds for use in the treatment of alzheimer's disease
ME03008B (me) 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
WO2013044099A1 (en) 2011-09-23 2013-03-28 Siemens Healthcare Diagnostics Inc. Cell response assay for cancer and methods of producing and using same
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US8764695B2 (en) 2012-09-28 2014-07-01 Isaac Eliaz Reduction of galectin-3 levels by plasmapheresis
ES2669068T3 (es) 2011-12-08 2018-05-23 Eliaz Therapeutics, Inc Reducción de niveles de galectina-3 mediante plasmaféresis
US9549953B2 (en) 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
CA2859202A1 (en) 2011-12-15 2013-06-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Identification of two novel biomarkers for niemann-pick disease type c
US20130164217A1 (en) 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
KR20140068105A (ko) 2011-12-29 2014-06-05 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드가 결합하여 성숙 신경 세포사를 유발하는 표적 분자, 아밀로스페로이드가 유도하는 신경 세포사를 억제하는 방법 및 물질, 및 그들의 이용
WO2013106572A1 (en) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013127829A1 (en) 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2013144957A1 (en) 2012-03-26 2013-10-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
WO2013169890A1 (en) 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
EP2847217B1 (en) 2012-05-10 2017-10-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
FR2994803B1 (fr) 2012-08-30 2016-02-26 Oreal Modulation de la forme des fibres keratiniques
US9655977B2 (en) 2012-08-31 2017-05-23 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
HK1212240A1 (en) 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
AU2013315019B2 (en) 2012-09-17 2017-06-01 Galectin Therapeutics, Inc. Method for enhancing specific immunotherapies in cancer treatment
DK3456734T3 (da) 2012-10-04 2022-04-19 Res Found Dev Serinproteasemolekyler og behandlinger
SMT202000340T1 (it) 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide
WO2014082083A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US9066928B1 (en) 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9433665B2 (en) 2013-01-11 2016-09-06 Cyvax, Inc. Vaccines for protection from and treatment of alzheimer's disease
JP6372040B2 (ja) 2013-02-06 2018-08-15 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
SI2961426T1 (sl) 2013-02-26 2020-01-31 Baxalta GmbH Zdravljanje motenj centralnega živčnega sistema z intranazalnim dajanjem imunoglobulina G
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
WO2014151747A1 (en) 2013-03-15 2014-09-25 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US9937231B2 (en) 2013-03-27 2018-04-10 The General Hospital Corporation Methods and agents for treating Alzheimer's disease
HUE044737T2 (hu) 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
WO2014194166A1 (en) 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease
EP3013355B1 (en) 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 for use in treating alzheimer disease and related disorders
US9645155B2 (en) 2013-08-28 2017-05-09 University Of South Florida Methods of synthesizing γ-aapeptides, γ-aapeptide building blocks, γ-aapeptide libraries, and γ-aapeptide inhibitors of Aβ40 aggregates
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
WO2015038446A1 (en) 2013-09-13 2015-03-19 Merck Sharp & Dohme Corp. C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use
WO2015051850A1 (en) 2013-10-11 2015-04-16 Universität Für Bodenkultur Wien Compositions containing galectin-3 modulators for the treatment of bone disorders
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
GB201319761D0 (en) 2013-11-08 2013-12-25 Nordic Bioscience As Biomarkers of disease progression
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
WO2015100353A1 (en) 2013-12-27 2015-07-02 Dignity Health Diagnosing and treating alzheimer's disease
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
EP3102230B1 (en) 2014-02-08 2021-04-28 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN103880963A (zh) * 2014-04-08 2014-06-25 江苏匡亚生物医药科技有限公司 半乳糖凝集素-3C（Galectin-3C) 抗体融合蛋白的制备方法和用途
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
ES2921180T3 (es) 2014-04-16 2022-08-19 Kyowa Kirin Co Ltd Método para medir la toxicidad del CSF humano
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
AU2015258814B2 (en) 2014-05-16 2018-04-05 Synaptec Development Llc Clearance of amyloid ss
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
US20150377905A1 (en) 2014-06-25 2015-12-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of kawasaki disease
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
GB2528098B (en) 2014-07-09 2018-11-21 Jaguar Land Rover Ltd Vehicle camera system
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
CN106796243B (zh) 2014-08-14 2018-10-12 国立大学法人广岛大学 判定早产和/或低体重儿生育的风险的方法和用于该方法的试剂盒
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN106794247B (zh) 2014-09-15 2022-12-02 豪夫迈·罗氏有限公司 抗体配制剂
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
US10328051B2 (en) 2014-09-22 2019-06-25 Zoser B. Salama Proline or proline derivatives for the treatment of dementia
US9921230B2 (en) 2014-10-08 2018-03-20 Rhode Island Hospital Methods for diagnosis and treatment of concussion or brain injury
WO2016059453A1 (en) 2014-10-16 2016-04-21 Fundacion Fraunhofer Chile Research Biomarkers and therapeutic targets for alzheimer's disease
US10837966B2 (en) 2014-11-04 2020-11-17 Dana-Farber Cancer Institute, Inc. Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
CN107428820B (zh) 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10654917B2 (en) 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
US11867696B2 (en) 2015-02-06 2024-01-09 Cell Idx, Inc. Antigen-coupled immunoreagents
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
GB201504432D0 (en) 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
US12109346B2 (en) 2015-03-27 2024-10-08 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
JP2018509994A (ja) 2015-03-27 2018-04-12 エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 患者選択的アフェレシス
GB201505239D0 (en) 2015-03-27 2015-05-13 Neuro Bio Ltd Antibody
CN115925932A (zh) 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
HK1248577A1 (zh) 2015-05-11 2018-10-19 F. Hoffmann-La Roche Ag 治疗狼疮性肾炎的组合物和方法
GB201508276D0 (en) 2015-05-14 2015-06-24 Electrophoretics Ltd A casein kinase 1 delta inhibitor
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3302561A4 (en) 2015-06-08 2019-02-06 Debiopharm International SA COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES
US10203342B2 (en) 2015-06-11 2019-02-12 Nanosomix, Inc. Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
CN114129737A (zh) 2015-06-30 2022-03-04 纳米提克斯有限责任公司 与清除颗粒相关的组合物和方法
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017027691A1 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
US11154620B2 (en) 2015-08-18 2021-10-26 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
US10282349B2 (en) 2015-08-26 2019-05-07 International Business Machines Corporation Method for storing data elements in a database
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
US20180360959A1 (en) 2015-09-25 2018-12-20 Universität Duisburg-Essen Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
CN108779167A (zh) 2015-10-28 2018-11-09 宾夕法尼亚州大学信托人 鞘内施用腺伴随病毒载体用于基因治疗
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
EP3397645B1 (en) 2015-12-28 2026-03-25 Innate Pharma Variable regions for nkp46 binding proteins
CN108779182A (zh) 2015-12-28 2018-11-09 麻省理工学院 具有恒定区突变的双特异性抗体及其用途
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
EP3423491A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab variants having altered cell death induction
MX394409B (es) * 2016-03-04 2025-03-24 Galectin Sciences Llc Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
WO2017172757A1 (en) 2016-03-29 2017-10-05 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
US11768203B2 (en) 2016-03-31 2023-09-26 University Of Southern California Highly sensitive and specific luciferase based reporter assay for antigen detection
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US9933440B2 (en) 2016-05-31 2018-04-03 Edward J. Goetzl Drug efficacy test method for dementias utilizing astrocyte-derived exosomes
WO2017218911A1 (en) 2016-06-17 2017-12-21 Abbott Laboratories BIOMARKERS TO PREDICT NEW ONSET HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
AU2017290703B2 (en) 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
PH12018502613B1 (en) 2016-07-12 2023-02-01 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018017604A1 (en) 2016-07-18 2018-01-25 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
CA3030754C (en) 2016-07-20 2022-04-26 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US10076552B2 (en) 2016-08-09 2018-09-18 DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof
WO2018030405A1 (ja) 2016-08-09 2018-02-15 国立大学法人東京医科歯科大学 Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
AU2017321609C1 (en) 2016-08-30 2023-11-09 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
WO2018058098A1 (en) 2016-09-26 2018-03-29 Yale University Compounds and methods for treating or preventing alzheimer's disease
KR102546471B1 (ko) 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
ES2834484T3 (es) 2016-11-21 2021-06-17 Univ Ruhr Bochum Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CN110312534B (zh) 2016-12-21 2023-04-04 拜耳制药股份公司 具有酶促可裂解基团的抗体-药物-缀合物(adc)
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CA3048224A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
WO2018129188A1 (en) 2017-01-04 2018-07-12 Nanotics, Llc Methods for assembling scavenging particles
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
WO2018138709A1 (en) 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US10473672B2 (en) 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
JP7165995B2 (ja) 2017-02-21 2022-11-07 アールイーエムディー バイオセラピューティクス，インコーポレイテッド 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
WO2018156617A2 (en) 2017-02-22 2018-08-30 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer / biomacromolecule conjugates
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
JP7330942B2 (ja) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
US20230399414A1 (en) 2017-03-31 2023-12-14 Genmab Holding B.V, Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN108728465A (zh) 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
CN113831417B (zh) 2017-05-08 2024-10-01 上海津曼特生物科技有限公司 双特异性重组蛋白及其应用
KR20200015528A (ko) 2017-05-12 2020-02-12 갈랙틴 사이언시즈, 엘엘씨 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도
WO2018210898A1 (en) 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
US11214835B1 (en) 2017-06-06 2022-01-04 University Of South Florida Methods and compositions for diagnosis and management of neurodegerative diseases
WO2018231759A1 (en) 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
US10662246B2 (en) 2017-07-10 2020-05-26 New York University Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
CN111133006A (zh) 2017-07-14 2020-05-08 西托姆克斯治疗公司 抗cd166抗体及其用途
CN107383192B (zh) * 2017-07-19 2018-08-24 深圳市倍诺博生物科技有限公司 半乳糖凝集素-3检测试剂盒
US20190029970A1 (en) 2017-07-31 2019-01-31 The Chinese University Of Hong Kong Fatty acid conjugated nanoparticles and uses thereof
BR112020001698A2 (pt) 2017-08-03 2020-07-21 Galectin Sciences, Llc compostos para prevenção e tratamento de distúrbios médicos e usos dos mesmos
IL272418B2 (en) 2017-08-08 2024-09-01 Hoffmann La Roche Abinotuzumab treatment of a new subgroup of DLBCL patients
CN107881160A (zh) 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
WO2019067805A1 (en) 2017-09-27 2019-04-04 University Of Southern California NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY
EP3466975A1 (en) 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein
US20200330592A1 (en) 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
MX2020003888A (es) 2017-10-18 2020-11-06 Regenxbio Inc Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
CN111770761B (zh) 2017-10-25 2024-07-09 爱兰细胞技术公司 H1.0k180me2抗体、其制造方法和用途
CA3080128A1 (en) 2017-10-31 2019-05-09 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019094679A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of California BRAIN DELIVERY OF THE BACE INHIBITOR SAPPALPHA, ANTIBODIES, OR INHIBITORY RNA's USING SYNTHETIC EXOSOMES (DEFORMABLE NANOVESICLES, DNVs)
PE20211453A1 (es) 2017-11-29 2021-08-05 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
EP3729081B1 (en) 2017-12-21 2025-02-19 F. Hoffmann-La Roche AG Car-t cell assay for specificity test of novel antigen binding moieties
CN109985231A (zh) 2018-01-02 2019-07-09 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗痴呆症的药物中的应用
EP3737472A1 (en) 2018-01-09 2020-11-18 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation
KR101868343B1 (ko) 2018-01-16 2018-06-18 재단법인대구경북과학기술원 콧물 시료의 베타 아밀로이드 올리고머를 이용한 알츠하이머 질환의 진행 단계 스크리닝용 조성물 및 이를 이용한 알츠하이머 질환의 진행 단계 스크리닝 방법
AU2019215202B2 (en) 2018-02-01 2025-11-13 Memorial Sloan Kettering Cancer Center Antibodies to Galectin-3 and methods of use thereof
US12398201B2 (en) 2018-02-19 2025-08-26 New York University Tau single domain antibodies
EP3755350A4 (en) 2018-02-23 2021-11-03 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND HIS ASSOCIATION PARTNER
WO2019165240A1 (en) 2018-02-23 2019-08-29 Rhnanopharma Nanosuspensions of salsalate and methods of using the same
EP3759145A4 (en) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
SG11202008098TA (en) 2018-03-28 2020-10-29 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
CN116173238A (zh) 2018-03-29 2023-05-30 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法
CN112584901A (zh) 2018-04-04 2021-03-30 真和制药有限公司 用于阻断非糖基化的pd-1多肽之间的相互作用的方法和组合物
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
JP7318948B2 (ja) 2018-04-13 2023-08-01 国立大学法人京都大学 微生物由来化合物を用いたアルツハイマー病の予防、治療、または診断薬
TWI874314B (zh) 2018-04-16 2025-03-01 瑞士商赫孚孟拉羅股份公司 螯合型放射核種之抗體
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019231957A1 (en) 2018-05-30 2019-12-05 National Health Research Institutes Anti-abeta antibodies and uses thereof
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019243453A1 (en) 2018-06-19 2019-12-26 Universidad Pablo De Olavide Compositions for treating and/or preventing protein-aggregation diseases
US12280063B2 (en) 2018-06-20 2025-04-22 Sanford Burnham Prebys Medical Discovery Institute Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease
CA3106212A1 (en) 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
US20210324056A1 (en) 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN121248772A (zh) 2018-08-17 2026-01-02 Ab工作室有限公司 催化抗体和其使用方法
JP7525160B2 (ja) 2018-08-31 2024-07-30 Ｂｌｏｏｍ Ｔｅｃｈｎｏｌｏｇｙ 株式会社 終末糖化産物に対する抗体およびその使用
CA3111569A1 (en) 2018-09-11 2020-03-19 Washington University Anti-trem-2 agonist antibodies
WO2020061232A1 (en) 2018-09-18 2020-03-26 1 Globe Biomedical Co., Ltd. Treatment for non-alcoholic fatty liver disease
EP3854875B1 (en) 2018-09-21 2026-01-14 Institute of Science Tokyo Human monoclonal antibody binding specifically to human hmgb1, and pharmaceutical composition for treating or preventing alzheimer's disease containing said human monoclonal antibody
BR112021006153A2 (pt) 2018-10-04 2021-06-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin anticorpo monoclonal beta amiloide anti-n-truncado humanizado
CN113508300A (zh) 2018-10-04 2021-10-15 曼尼托巴大学 用于人类阿尔茨海默病的新型生物标记物
CN120623346A (zh) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
EP3867267A1 (en) 2018-10-18 2021-08-25 FundaMental Pharma GmbH Novel means to modulate nmda receptor-mediated toxicity
EP3643319A1 (en) 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
US20220089704A1 (en) 2018-10-29 2022-03-24 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
BR112021008139A2 (pt) 2018-10-29 2021-08-03 Cyclo Therapeutics, Inc. métodos para tratar doença de alzheimer
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
JP2022510218A (ja) 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
CN121714327A (zh) 2018-12-04 2026-03-24 脑部保护私人有限公司 包括用于治疗病症的可植入阻尼装置和治疗剂的组合疗法及相关系统和使用方法
US12365724B2 (en) 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
CA3122321A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
JP2022037257A (ja) 2018-12-27 2022-03-09 クリニジェン株式会社 アルツハイマー病を治療又は予防する為の抗ウイルス剤及びその使用
EP3911371A4 (en) 2019-01-18 2023-04-26 University of Southern California METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CN111518205B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
WO2020163817A1 (en) 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau
MY206596A (en) 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
PL240124B1 (pl) 2019-02-21 2022-02-21 Univ Jagiellonski Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą
CA3131019A1 (en) 2019-02-22 2020-08-27 Memorial Sloan Kettering Cancer Center Cd33 antibodies and methods of using the same to treat cancer
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
US20220160710A1 (en) 2019-03-08 2022-05-26 University Of Virginia Patent Foundation Compositions and methods for treating or preventing alzheimer's disease
KR20220022112A (ko) 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법
JOP20210265A1 (ar) 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
CN113661172A (zh) 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
SG11202110810WA (en) 2019-03-29 2021-10-28 Torque Therapeutics Inc Immunotherapeutic compositions and use thereof
CN113795262A (zh) 2019-04-08 2021-12-14 东莞凡恩世生物医药有限公司 人源化抗dll3嵌合抗原受体及其用途
WO2020219868A1 (en) 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
JOP20210284A1 (ar) 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
DE202020006093U1 (de) 2019-05-06 2025-04-09 The Regents Of The University Of California Nicht-HLA-Marker der Transplantatabstoßung
US20230212250A1 (en) 2019-05-09 2023-07-06 University Of The Witwatersrand, Johannesburg A method of decreasing concentration of tau (t) protein and/or phosphorylated tau (t) protein
AU2020275415B2 (en) 2019-05-14 2026-01-15 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
US20220226514A1 (en) 2019-05-17 2022-07-21 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
CA3141334A1 (en) 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
CN116987197A (zh) 2019-06-20 2023-11-03 成都恩沐生物科技有限公司 共价多特异性抗体
JP2022544640A (ja) 2019-06-21 2022-10-20 ユニバーシティ オブ カンザス 脳疾患の治療に有用な組成物および方法
CA3143519A1 (en) 2019-06-26 2020-12-30 Volker Schellenberger Cd3 antigen binding fragments and compositions comprising same
WO2020264211A1 (en) 2019-06-26 2020-12-30 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
KR20220027993A (ko) 2019-06-28 2022-03-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 알츠하이머 질환을 치료하기 위한 방법 및 조성물
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
EP3994159A4 (en) 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
JP7194085B2 (ja) 2019-07-09 2022-12-21 日立Astemo株式会社 操舵制御装置、操舵制御方法、及び操舵制御システム
WO2021009646A1 (en) 2019-07-15 2021-01-21 Cochlear Limited Transcutaneous power and data communication link
CN115175932B (zh) 2019-07-16 2025-10-31 赛诺菲 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
EP4002490A4 (en) 2019-07-17 2023-04-05 Kabushiki Kaisha Toshiba SOLAR BATTERY MODULE AND TANDEM SOLAR BATTERY
US20220275037A1 (en) 2019-07-19 2022-09-01 Dingding MO ß-AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF
CA3147020A1 (en) 2019-08-07 2021-02-11 Joe G.N. Garcia Anti-nampt antibodies and uses thereof
WO2021028590A1 (en) 2019-08-14 2021-02-18 Boehringer Ingelheim Rcv Gmbh & Co Kg Caspase-2 variants
WO2021041678A1 (en) 2019-08-30 2021-03-04 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
US20220332757A1 (en) 2019-09-09 2022-10-20 Wuhan Yzy Biopharma Co., Ltd. Split intein and preparation method for recombinant polypeptide using the same
WO2021050601A1 (en) 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
JP2022547513A (ja) 2019-09-09 2022-11-14 アクソン ニューロサイエンス エスエー アルツハイマー病及び軽度認知障害のバイオマーカー及び治療
CN114340675A (zh) 2019-09-12 2022-04-12 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
BR112022005044A2 (pt) 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
AU2020351205A1 (en) 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
US20230340157A1 (en) 2019-09-27 2023-10-26 Beijing Starmab Biomed Technology Ltd Monospecific and multi-specific antibodies
AR122307A1 (es) 2019-10-04 2022-08-31 Chugai Pharmaceutical Co Ltd Agente de supresión de la proliferación celular de cáncer cd20 positivo tolerante a obinutuzumab, y composición farmacéutica, medicamento, fabricación, procedimiento de supresión de la proliferación celular, procedimiento de tratamiento, anticuerpo anti-cd20 de tipo ii, compuesto, sus combinaciones, y agente potenciador y agente inductor, relacionados con estos
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN112641953A (zh) 2019-10-10 2021-04-13 复旦大学 一种靶向功能分子修饰的抗体复合物
KR20220084095A (ko) 2019-10-22 2022-06-21 바이오젠 엠에이 인코포레이티드 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CN115427439A (zh) 2019-10-30 2022-12-02 德克萨斯A&M大学系统 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关
GB201915855D0 (en) 2019-10-31 2019-12-18 Univ Oxford Innovation Ltd An extracellular vesicle
EP4065600A1 (en) 2019-11-25 2022-10-05 Cornell University Apoe gene therapy
AU2020390448A1 (en) 2019-11-28 2022-07-14 Mcmaster University Recombinant polypeptides for programming extracellular vesicles
US20230046007A1 (en) 2019-12-17 2023-02-16 Cirlo Gmbh Tubular shaped elongated catheter device assemblies for interacting with components of bodily fluids, method for recovering cells, cell aggregates and exosomes from a tubular shaped elongated catheter device and smart tubular shaped elongated catheter device assemblies for monitoring interaction with components of bodily fluids
EP4085251B1 (en) 2020-01-02 2024-07-31 F. Hoffmann-La Roche AG Method for determining the amount of a therapeutic antibody in the brain
EP4095159A4 (en) 2020-01-21 2024-03-20 Shanghai Henlius Biotech, Inc. MONOCLONAL ANTI-LAG3 ANTIBODY AND METHOD FOR THE PRODUCTION THEREOF AND ITS USE
JP7789002B2 (ja) 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
CN115066610A (zh) 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法
JP2023514972A (ja) 2020-02-12 2023-04-12 ザ スクリプス リサーチ インスティテュート 長時間作用型ｇｍ－ｃｓｆおよび使用方法
WO2021163681A2 (en) 2020-02-14 2021-08-19 The Trustees Of Columbia University In The City Of New York Combination of retromer pharmacological chaperones and exogenous retromer for the treatment of alzheimer's disease and other neurodegenerative diseases and disorders
EP4107177A4 (en) 2020-02-17 2024-06-19 Board of Regents, The University of Texas System CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTHO) AND USES THEREOF
US12595311B2 (en) 2020-03-02 2026-04-07 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
GB202003428D0 (en) 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens
CN113384710A (zh) 2020-03-14 2021-09-14 杭州星鳌生物科技有限公司 新型免疫激动剂复合物的组成及其在抗多种疾病药物中的应用
CA3171906A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US20230212255A1 (en) 2020-03-17 2023-07-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
US20230104705A1 (en) 2020-03-17 2023-04-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
US20230143984A1 (en) 2020-03-20 2023-05-11 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action
WO2021195020A1 (en) 2020-03-23 2021-09-30 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
EP4122489A4 (en) 2020-03-24 2023-04-12 Talengen International Limited METHODS AND MEDICATIONS FOR PROMOTING THE BREAKDOWN OF MISFOLDED PROTEIN AND AGGREGATE THEREOF
US20230173039A1 (en) 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
CA3174188A1 (en) 2020-03-31 2021-10-07 Neil R. Cashman Antibodies to misfolded amyloid beta
WO2021207312A1 (en) 2020-04-07 2021-10-14 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating retinal nerve damage
WO2021207273A1 (en) 2020-04-07 2021-10-14 The Regents Of The University Of California Manufacturing of synthetic exosomes for cns and non-cns delivery of therapeutics
US20230265204A1 (en) 2020-04-24 2023-08-24 Hoffmann-La Roche Inc. Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
BR112022023366A2 (pt) 2020-05-19 2023-05-02 Othair Prothena Ltd Vacina com múltiplos epítopos para o tratamento de mal de alzheimer
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
EP4157241A4 (en) 2020-05-29 2025-01-08 The Regents of the University of California AGENTS AND METHODS FOR THE TREATMENT OF TAUOPATHIES
EP4157462A1 (en) 2020-06-02 2023-04-05 Dynamicure Biotechnology LLC Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2021248081A1 (en) 2020-06-05 2021-12-09 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Acvr1 (alk2) receptor inhibition to treat neurological diseases
KR102225447B1 (ko) 2020-06-16 2021-03-08 부산대학교 산학협력단 구강 세균의 군집을 이용한 알츠하이머 진단용 바이오마커 및 이의 용도
PE20230470A1 (es) 2020-06-19 2023-03-14 Hoffmann La Roche Moleculas de union al dominio fc de activacion inmunitaria
WO2021260193A1 (en) 2020-06-25 2021-12-30 Medimmune Limited Prevention of axonal damage using antibody binding to amyloid beta 1-42
US20210403644A1 (en) 2020-06-29 2021-12-30 University Of South Carolina Method For The Degradation Of Endogenous Protein
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用
TW202216777A (zh) 2020-07-10 2022-05-01 美商生質分子控股有限責任公司 四面體抗體
WO2022020232A1 (en) 2020-07-20 2022-01-27 Genentech, Inc. Methods for middle down antibody characterization
IL299950A (en) 2020-07-20 2023-03-01 Neotx Therapeutics Ltd Superantigen conjugate for use in methods and compositions for the treatment of cancer
EP4185705A4 (en) 2020-07-21 2025-01-22 Amunix Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ACTIVATED THERAPEUTIC AGENTS
US20230322935A1 (en) 2020-07-29 2023-10-12 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
EP4188408A1 (en) 2020-07-30 2023-06-07 Unigen, Inc. A standardized bioflavonoid composition for regulation of homeostasis of host defense mechanism
EP4188441A1 (en) 2020-07-30 2023-06-07 AnaptysBio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022029051A1 (en) 2020-08-03 2022-02-10 F. Hoffmann-La Roche Ag Improved antigen binding receptors
JP2023536602A (ja) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
MX2023001501A (es) 2020-08-07 2023-03-08 Prothena Biosciences Ltd Vacuna tau para tratamiento de enfermedad de alzheimer.
WO2022032166A1 (en) 2020-08-07 2022-02-10 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease
IL300534A (en) 2020-08-11 2023-04-01 Kanaph Therapeutics Inc A fusion protein containing 12-il and an anti-fap antibody, and its use
EP4186926A4 (en) 2020-08-28 2024-06-05 Harbour Biomed US, Inc. ANTI-CCR8 ANTIBODIES AND CORRESPONDING APPLICATION
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
US20230364210A1 (en) 2020-09-17 2023-11-16 Othair Prothena Limited ß-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER’S DISEASE
JP2023541482A (ja) 2020-09-18 2023-10-02 ピエリス ファーマシューティカルズ ゲーエムベーハー バイオマーカー法および使用法
CN116438191A (zh) 2020-09-18 2023-07-14 欧萨尔普罗席纳有限公司 治疗阿尔茨海默病之多表位疫苗
KR20230074146A (ko) 2020-09-24 2023-05-26 에프. 호프만-라 로슈 아게 T 세포 이중특이성 항체 관련 역효과의 예방 또는 완화
WO2022072538A1 (en) 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
CA3198102A1 (en) 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
EP4010378B1 (en) 2020-10-16 2026-05-06 LaNova Medicines Limited Anti-ccr8 monoclonal antibodies and uses thereof
JP2023547447A (ja) 2020-10-28 2023-11-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 改良型抗原結合受容体
WO2022101120A1 (en) 2020-11-10 2022-05-19 F. Hoffmann-La Roche Ag Prevention or mitigation of t-cell engaging agent-related adverse effects
WO2022125482A1 (en) 2020-12-08 2022-06-16 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
JP2024503826A (ja) 2021-01-06 2024-01-29 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１－ｌａｇ３二重特異性抗体及びｃｄ２０ ｔ細胞二重特異性抗体を用いる併用療法
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
EP4284824A4 (en) 2021-01-27 2025-03-12 AbelZeta Inc. CHIMERIC ANTIGEN RECEPTORS TARGETING CD20
EP4286406A4 (en) 2021-01-29 2025-07-23 Illimis Therapeutics Inc FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY
KR20230153529A (ko) 2021-02-19 2023-11-06 프리트 엠. 쇼드하리 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체
AU2022238526A1 (en) 2021-03-15 2023-09-07 F. Hoffmann-La Roche Ag Compositions and methods of treating lupus nephritis
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
CA3213625A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
AU2022241940A1 (en) 2021-03-23 2023-10-26 Pieris Pharmaceuticals Gmbh Her2/4-1bb bispecific fusion proteins for the treatment of cancer
WO2022200478A1 (en) 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
WO2022204282A1 (en) 2021-03-24 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022212918A1 (en) 2021-04-02 2022-10-06 The Board Of Trustees Of The Leland Stanford Junior University Bispecific molecules and related compositions and methods
CN117597150A (zh) 2021-04-20 2024-02-23 思进公司 抗体依赖性细胞毒性的调节
WO2022223651A1 (en) 2021-04-23 2022-10-27 F. Hoffmann-La Roche Ag Prevention or mitigation of nk cell engaging agent-related adverse effects
JP2024515968A (ja) 2021-04-26 2024-04-11 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体製剤およびその使用法
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
TW202244059A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
WO2022235622A2 (en) 2021-05-04 2022-11-10 Biocove Llc Cd20 targeting fusion proteins and methods of use thereof
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
JP2024518536A (ja) 2021-05-12 2024-05-01 アナプティスバイオ インコーポレイティッド 抗体組成物
IL308351A (en) 2021-05-12 2024-01-01 Genentech Inc Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4347042A1 (en) 2021-06-04 2024-04-10 Xencor, Inc. Dosing of a bispecific antibody that binds cd20 and cd3
US20220411514A1 (en) 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
KR20240019786A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
IL308918A (en) 2021-06-09 2024-01-01 Shanghai Epimab Biotherapeutics Co Ltd Antibodies and bispecific binding proteins that bind OX40 and/or PD-L1
WO2022266539A2 (en) 2021-06-18 2022-12-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
US20240279321A1 (en) 2021-06-18 2024-08-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
US20240189341A1 (en) 2021-06-22 2024-06-13 Remegen Co., Ltd. Pharmaceutical combination and use thereof
KR20240025013A (ko) 2021-06-25 2024-02-26 난징 이뮤노파지 바이오테크 코., 엘티디. 항-ccr8 항체 및 이의 용도
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
JP7826449B2 (ja) 2021-07-13 2026-03-09 ジェネンテック， インコーポレイテッド サイトカイン放出症候群を予測する多変量モデル
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2023019216A2 (en) 2021-08-13 2023-02-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating ischemic eye disease
CN118251411A (zh) 2021-09-29 2024-06-25 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
WO2023051727A1 (zh) 2021-09-30 2023-04-06 上海君实生物医药科技股份有限公司 结合cd3的抗体及其用途
AR127271A1 (es) 2021-10-09 2024-01-03 Hutchmed Ltd Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
CN115746134A (zh) 2021-10-15 2023-03-07 深圳市睿盟创新生物科技有限公司 半乳糖凝集素-3的免疫测定
KR20230060546A (ko) 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
US20250011418A1 (en) 2021-10-29 2025-01-09 Zielbio, Inc. Cancer specific plectin-1 specific antibodies and methods of use thereof
CN118524852A (zh) 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
IL312652A (en) 2021-11-25 2024-07-01 Hoffmann La Roche Enhanced receptors for antigen binding
CN118524854A (zh) 2021-12-17 2024-08-20 北京加科思新药研发有限公司 包含可用作sting激动剂的新型化合物的化合物-连接基构建体及其用途
WO2023116880A1 (en) 2021-12-23 2023-06-29 Concept To Medicine Biotech Co., Ltd. Anti-ccr8 antibodies and uses thereof
EP4458861A1 (en) 2021-12-29 2024-11-06 Sichuan Huiyu Pharmaceutical Co., Ltd. Antibody targeting cd3, multispecific antibody, and uses thereof
MX2024008641A (es) 2022-01-12 2024-07-24 Biomolecular Holdings Llc Anticuerpos tetraedricos.
US20230220115A1 (en) 2022-01-12 2023-07-13 Biomolecular Holdings Llc Tetrahedral antibodies
CN116462765A (zh) 2022-01-20 2023-07-21 上海君实生物医药科技股份有限公司 抗cd3和抗cd20双特异性抗体及其用途
US20250388669A1 (en) 2022-01-21 2025-12-25 Jieyi Wang Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
KR20230119859A (ko) 2022-02-08 2023-08-16 연세대학교 산학협력단 신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
TW202400643A (zh) 2022-02-28 2024-01-01 日商帝人製藥股份有限公司 神經退化性疾病之治療劑
GB202203070D0 (en) 2022-03-04 2022-04-20 Iksuda Therapeutics Ltd Anti-canag antibody conjugate
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
CN116789820A (zh) 2022-03-18 2023-09-22 北京天诺健成医药科技有限公司 一种新型免疫调节剂的开发和应用
MX2024011468A (es) 2022-03-23 2024-09-25 Hoffmann La Roche Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
JP2025512798A (ja) 2022-03-25 2025-04-22 サイトムエックス セラピューティクス，インク． 活性化可能な二重アンカー型マスク化分子及びその使用方法
US20250215091A1 (en) 2022-03-25 2025-07-03 Les Laboratoires Servier Anti-GAL3 Antibodies and Compositions
EP4504794A1 (en) 2022-04-04 2025-02-12 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
US20250223364A1 (en) 2022-04-04 2025-07-10 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
US20250346681A1 (en) 2022-04-11 2025-11-13 Astrazeneca Ab T cell binding proteins
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023201299A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of therapeutic proteins and methods of use
AU2023253036A1 (en) 2022-04-15 2024-10-17 Mabsoft Therapeutics Conjugate comprising toll-like receptor agonist
CN117003872A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
AU2023264582A1 (en) 2022-05-03 2024-11-21 Incyte Corporation Methods for treating lymphoma
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
JP2025517476A (ja) 2022-05-25 2025-06-05 イナート・ファルマ・ソシエテ・アノニム ネクチン－４結合剤
US20230416412A1 (en) 2022-05-31 2023-12-28 Hoffmann-La Roche Inc. Prevention or mitigation of t-cell engaging agent-related adverse effects
CN117323429A (zh) 2022-07-01 2024-01-02 广东克冠达医药科技有限公司 Cd101的抗体及其用途
JP2025524628A (ja) 2022-07-12 2025-07-30 シートムエックス セラピューティクス，インコーポレイテッド Ｅｐｃａｍイムノコンジュゲート及びその使用
EP4562058A1 (en) 2022-07-28 2025-06-04 The Board of Regents of the University of Oklahoma Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases
JP2025525904A (ja) 2022-08-03 2025-08-07 シージェン インコーポレイテッド 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート
WO2024036148A1 (en) 2022-08-08 2024-02-15 A2 Biotherapeutics, Inc. Compositions and methods for treating blood cancers
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024220435A1 (en) 2023-04-18 2024-10-24 Truebinding, Inc. Methods of treating eye disease
CN117051537A (zh) 2023-07-03 2023-11-14 五邑大学 一种乙酰化葡甘聚糖静电纺丝膜及其制备方法与应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143954A1 (en) * 2008-10-29 2010-06-10 Bg Medicine, Inc. Galectin-3 Immunoassay
US20150218274A1 (en) * 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof
JP2017511687A (ja) * 2014-01-31 2017-04-27 ノバルティス アーゲー Ｔｉｍ−３に対する抗体分子およびその使用
JP2017512205A (ja) * 2014-03-10 2017-05-18 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎臓障害を治療するための組成物及び方法
WO2019023247A1 (en) * 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
JP2023504199A (ja) * 2019-12-06 2023-02-01 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
JP2023510866A (ja) * 2020-01-13 2023-03-15 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体および使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548627A (ja) * 2019-09-16 2022-11-21 ノバルティス アーゲー 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
JP7802400B1 (ja) * 2024-10-18 2026-01-20 Ｓｍｃグローバルアセット株式会社 物質の投与による効果の評価を行う方法

Also Published As

Publication number Publication date
CA3127113A1 (en) 2020-08-06
WO2020160156A3 (en) 2020-09-17
KR20210124308A (ko) 2021-10-14
JP2025074121A (ja) 2025-05-13
US20220380473A1 (en) 2022-12-01
CN113711036A (zh) 2021-11-26
US11427638B2 (en) 2022-08-30
WO2020160156A2 (en) 2020-08-06
CN116063520A (zh) 2023-05-05
EP3918323A4 (en) 2022-12-28
AU2020214796A1 (en) 2021-07-29
CN116063505A (zh) 2023-05-05
CN116063505B (zh) 2024-05-03
US20220002420A1 (en) 2022-01-06
EP3918323A2 (en) 2021-12-08
US12497458B2 (en) 2025-12-16
CN120058944A (zh) 2025-05-30
CN113711036B (zh) 2025-03-18

Similar Documents

Publication Publication Date Title
US12497458B2 (en) Anti-GAL3 antibodies and uses thereof
CN113423735B (zh) 抗-紧密连接蛋白抗体及其用途
JP7084569B2 (ja) Ｖｉｓｔａ及びその結合パートナーの相互作用を遮断することによる癌治療
RU2708075C2 (ru) Конъюгаты анти-ртк7 антитело-лекарственное средство
EP3661555B1 (en) Bispecific antibodies and uses thereof
TW200938629A (en) Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
CN112424231B (zh) 抗pd-1抗体及其剂量和用途
JP7835441B2 (ja) Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
TW202426498A (zh) Ccr8抗體之醫藥用途及給藥計劃
CN117693529A (zh) 抗uPAR抗体和其用途
HK40064218B (zh) 抗gal3抗体及其用途
HK40064218A (zh) 抗gal3抗体及其用途
RU2815926C2 (ru) Антитела против клаудина и их применение
US20220281973A1 (en) Antibodies and blocking the interaction of vista and its binding partner
HK40129144A (zh) 抗il-1rap抗体、其药物组合物及用途
HK40059021A (en) Anti-claudin antibodies and uses thereof
HK40059021B (zh) 抗-紧密连接蛋白抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250729

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20251125